80 related articles for article (PubMed ID: 24158177)
1. Effect of combined bevacizumab and temozolomide treatment on intramedullary spinal cord tumor.
Gwak SJ; An SS; Yang MS; Joe E; Kim DH; Yoon DH; Kim KN; Ha Y
Spine (Phila Pa 1976); 2014 Jan; 39(2):E65-73. PubMed ID: 24158177
[TBL] [Abstract][Full Text] [Related]
2. Combination Therapy by Tissue-Specific Suicide Gene and Bevacizumab in Intramedullary Spinal Cord Tumor.
Gwak SJ; Che L; Yun Y; Lee M; Ha Y
Yonsei Med J; 2020 Dec; 61(12):1042-1049. PubMed ID: 33251778
[TBL] [Abstract][Full Text] [Related]
3. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
[TBL] [Abstract][Full Text] [Related]
4. The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Grossman R; Rudek MA; Brastianos H; Zadnik P; Brem H; Tyler B; Blakeley JO
Cancer Chemother Pharmacol; 2012 Jul; 70(1):129-39. PubMed ID: 22644796
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Chamberlain MC
Cancer; 2008 Sep; 113(5):1019-24. PubMed ID: 18615600
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide or bevacizumab for spinal cord high-grade gliomas.
Kaley TJ; Mondesire-Crump I; Gavrilovic IT
J Neurooncol; 2012 Sep; 109(2):385-9. PubMed ID: 22678696
[TBL] [Abstract][Full Text] [Related]
7. A novel model of intramedullary spinal cord tumors in rats: functional progression and histopathological characterization.
Caplan J; Pradilla G; Hdeib A; Tyler BM; Legnani FG; Bagley CA; Brem H; Jallo G
Neurosurgery; 2006 Jul; 59(1):193-200; discussion 193-200. PubMed ID: 16823316
[TBL] [Abstract][Full Text] [Related]
8. Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model.
Zhang X; Guo M; Shen L; Hu S
Photodiagnosis Photodyn Ther; 2014 Dec; 11(4):603-12. PubMed ID: 25449156
[TBL] [Abstract][Full Text] [Related]
9. In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab.
Combs SE; Schulz-Ertner D; Roth W; Herold-Mende C; Debus J; Weber KJ
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):873-82. PubMed ID: 17544000
[TBL] [Abstract][Full Text] [Related]
10. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Kim JT; Kim JS; Ko KW; Kong DS; Kang CM; Kim MH; Son MJ; Song HS; Shin HJ; Lee DS; Eoh W; Nam DH
Oncol Rep; 2006 Jul; 16(1):33-9. PubMed ID: 16786120
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
Toshimitsu H; Yoshimoto Y; Augustine CK; Padussis JC; Yoo JS; Angelica Selim M; Pruitt SK; Friedman HS; Ali-Osman F; Tyler DS
Ann Surg Oncol; 2010 Aug; 17(8):2247-54. PubMed ID: 20182810
[TBL] [Abstract][Full Text] [Related]
12. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H
Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
Yoshino A; Tashiro S; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Sano E; Tsumoto K
Int J Oncol; 2011 Sep; 39(3):529-42. PubMed ID: 21805051
[TBL] [Abstract][Full Text] [Related]
14. Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
Sasajima T; Ono T; Shimada N; Doi Y; Oka S; Kanagawa M; Baden A; Mizoi K
Nucl Med Biol; 2013 Aug; 40(6):808-15. PubMed ID: 23701701
[TBL] [Abstract][Full Text] [Related]
15. Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab.
Vargo JA; Snelling BM; Ghareeb ER; John K; Frame JN; Schmidt JH; Peters KB
J Neurooncol; 2011 Sep; 104(2):595-8. PubMed ID: 21221711
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Marzolini C; Decosterd LA; Shen F; Gander M; Leyvraz S; Bauer J; Buclin T; Biollaz J; Lejeune F
Cancer Chemother Pharmacol; 1998; 42(6):433-40. PubMed ID: 9788568
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of temozolomide treatment in patients with high-grade glioma.
Oshiro S; Tsugu H; Komatsu F; Ohmura T; Ohta M; Sakamoto S; Fukushima T; Inoue T
Anticancer Res; 2009 Mar; 29(3):911-7. PubMed ID: 19414327
[TBL] [Abstract][Full Text] [Related]
18. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.
Brem S; Tyler B; Li K; Pradilla G; Legnani F; Caplan J; Brem H
Cancer Chemother Pharmacol; 2007 Oct; 60(5):643-50. PubMed ID: 17256133
[TBL] [Abstract][Full Text] [Related]
19. Current evidence of temozolomide and bevacizumab in treatment of gliomas.
Nanegrungsunk D; Onchan W; Chattipakorn N; Chattipakorn SC
Neurol Res; 2015 Feb; 37(2):167-83. PubMed ID: 25033940
[TBL] [Abstract][Full Text] [Related]
20. Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.
Czabanka M; Bruenner J; Parmaksiz G; Broggini T; Topalovic M; Bayerl SH; Auf G; Kremenetskaia I; Nieminen M; Jabouille A; Mueller S; Harms U; Harms C; Koch A; Heppner FL; Vajkoczy P
Eur J Cancer; 2013 Jun; 49(9):2243-52. PubMed ID: 23499430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
